Mesalazine Prolonged Release Tablets 1.2g — Complete Product Guide.

Mesalazine Prolonged Release Tablets are a clinically trusted anti-inflammatory medication specifically formulated to manage and maintain remission in ulcerative colitis and Crohn's disease. Designed with advanced prolonged-release technology, these tablets deliver the active ingredient — mesalazine (also known as 5-aminosalicylic acid or 5-ASA) — directly and steadily to the inflamed regions of the gastrointestinal tract, where therapeutic action is needed most.

Unlike immediate-release formulations, the prolonged-release design ensures a controlled, sustained delivery mechanism that maximizes drug concentration at the site of inflammation while minimizing systemic absorption and associated side effects.

What Are Mesalazine Prolonged Release Tablets?

Mesalazine Prolonged Release Tablets are a pharmaceutical-grade oral medication belonging to the aminosalicylate class of drugs. Each tablet contains 1.2g of mesalazine as the active substance, enclosed in a film-coated, prolonged-release matrix that prevents premature dissolution in the stomach. The tablet is designed to remain intact through the acidic gastric environment and gradually release mesalazine throughout the small intestine and colon — the primary sites of inflammation in IBD patients.

Active Ingredient: Mesalazine (5-aminosalicylic acid) — 1.2g per tablet Drug Class: Aminosalicylate / Anti-inflammatory Release Mechanism: Prolonged-release (time and pH-dependent) Route of Administration: Oral

Key Therapeutic Uses

Who are Mesalazine Prolonged Release Tablets prescribed for?

These tablets are clinically indicated for:

• Ulcerative Colitis (UC): Treatment of mild to moderate active ulcerative colitis and maintenance of remission once symptoms are controlled.

• Crohn's Disease: Management of ileal and ileocolonic Crohn's disease, particularly during active flare-ups.

• Long-Term IBD Maintenance: Prevention of relapse in patients with confirmed remission, reducing the frequency and severity of recurring episodes.

Gastroenterologists commonly prescribe this formulation when patients require consistent, round-the-clock gastrointestinal anti-inflammatory coverage without frequent dosing.

How Do Mesalazine Prolonged Release Tablets Work?

Mesalazine works by inhibiting the production of pro-inflammatory mediators — particularly prostaglandins and leukotrienes — within the intestinal mucosa. This action directly suppresses the local inflammatory response in the colon and small intestine without significantly impacting systemic immunity.

The prolonged-release coating is the distinguishing feature of this formulation. It enables:

• Targeted delivery to the terminal ileum and colon

• Sustained therapeutic concentration over an extended period

• Reduced dosing frequency, improving patient compliance

• Lower risk of systemic exposure, minimizing kidney and liver burden compared to older sulphasalazine-based therapies

This makes Mesalazine Prolonged Release Tablets a preferred first-line treatment for many IBD patients and a safer long-term maintenance option compared to corticosteroids.

Dosage and Administration — What You Should Know

The prescribed dosage of Mesalazine Prolonged Release Tablets varies based on the severity of the condition and individual patient factors. General clinical guidance includes:

• Active Disease (Induction): Higher doses, typically up to 4.8g per day (four 1.2g tablets), administered in divided doses as directed by a physician.

• Maintenance Therapy (Remission): Lower doses, commonly 2.4g per day (two 1.2g tablets), to sustain remission and prevent relapse.

Tablets should be swallowed whole with a full glass of water. They must not be broken, crushed, or chewed, as doing so will disrupt the prolonged-release mechanism, leading to premature drug release and reduced efficacy.

Always follow the dosage and schedule prescribed by your gastroenterologist or healthcare provider.

Safety Profile and Side Effects

Mesalazine Prolonged Release Tablets are generally well tolerated. The most commonly reported side effects are mild and transient, including:

• Nausea or abdominal discomfort

• Headache

• Diarrhea or loose stools

• Flatulence

Rare but serious adverse reactions — such as acute intolerance syndrome, renal impairment, or hypersensitivity reactions — require immediate medical attention. Patients with known salicylate hypersensitivity, severe renal or hepatic impairment, or peptic ulcer disease should consult their physician before use.

Regular monitoring of renal function is recommended for patients on long-term therapy.

Why Choose Mesalazine Prolonged Release Tablets 1.2g?

The 1.2g prolonged-release format offers a clinically validated, patient-friendly approach to IBD management. Compared to lower-strength immediate-release alternatives, it provides:

• Fewer daily tablets required for therapeutic dosing

• Consistent drug levels with reduced peak-trough fluctuation

• Greater convenience for patients managing chronic conditions

• Proven efficacy data supporting both induction and maintenance outcomes

Manufactured to GMP-certified pharmaceutical standards, Mesalazine Prolonged Release Tablets 1.2g represent a reliable, high-quality treatment option for healthcare professionals and patients seeking effective long-term inflammatory bowel disease management.